Ashford Capital Management Inc. Has $430,000 Position in Johnson & Johnson (JNJ)

Ashford Capital Management Inc. maintained its stake in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 3,250 shares of the company’s stock at the close of the second quarter. Ashford Capital Management Inc.’s holdings in Johnson & Johnson were worth $430,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of JNJ. Harding Loevner LP bought a new position in Johnson & Johnson during the second quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. lifted its position in Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the last quarter. IHT Wealth Management LLC lifted its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after purchasing an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson during the second quarter valued at $124,000. Hedge funds and other institutional investors own 65.89% of the company’s stock.

Several research firms have commented on JNJ. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price objective for the company. in a research report on Monday, September 18th. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Citigroup increased their price objective on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. BMO Capital Markets increased their price objective on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Jefferies Group upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price objective for the company from $145.00 to $157.00 in a research report on Wednesday, October 11th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $145.04.

Johnson & Johnson (NYSE JNJ) traded up $0.39 during trading on Friday, hitting $142.04. 4,929,567 shares of the stock traded hands, compared to its average volume of 5,869,776. The company has a market cap of $383,984.28, a price-to-earnings ratio of 20.02, a PEG ratio of 2.90 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 12-month low of $110.76 and a 12-month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $1.68 EPS. equities analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were issued a $0.84 dividend. The ex-dividend date was Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.37%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

COPYRIGHT VIOLATION NOTICE: “Ashford Capital Management Inc. Has $430,000 Position in Johnson & Johnson (JNJ)” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://sportsperspectives.com/2017/12/15/ashford-capital-management-inc-has-430000-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply